Needle-Free Adrenaline Nasal Spray Approved in the UK: A Breakthrough for Anaphylaxis Treatment

When you or someone you love lives with serious allergies, the risk of anaphylaxis is always at the back of your mind. The good news? The MHRA (Medicines and Healthcare products Regulatory Agency) has just approved the UK’s first needle-free adrenaline nasal spray – called EURneffy® – offering a new, simple way to treat life-threatening allergic reactions.

What Is Anaphylaxis?

Anaphylaxis is a severe and potentially life-threatening allergic reaction. It usually happens within minutes of exposure to an allergen such as:

• certain foods (e.g. peanuts, shellfish, dairy)

• insect stings

• medicines (e.g. antibiotics, painkillers)

• latex

Signs of anaphylaxis can include:

• difficulty breathing or swallowing

• swelling of the lips, tongue, or throat

• dizziness or fainting

• rapid heartbeat

• skin reactions such as hives or flushing

Without rapid treatment, anaphylaxis can be fatal. That’s why immediate access to adrenaline (epinephrine) is essential.

A Needle-Free Option: EURneffy® Nasal Spray

Until now, adrenaline auto-injectors like EpiPen® or Jext® have been the standard treatment in the UK. These remain vital, but EURneffy® is the first approved nasal spray alternative for people weighing 30 kg (around 4½ stone) or more.

Key Benefits

• No needle required – helps reduce fear and hesitation in emergencies.

• Fast and reliable – delivers a full 2 mg dose even if you have a blocked nose.

• Long shelf life – up to 30 months.

• Travel-friendly – stable at higher temperatures, making it easier to carry in different environments.

How to Use It

• Always carry two doses in case symptoms do not improve.

• Place the device correctly in the nostril before pressing – do not activate it early, as this releases the full dose.

• After using, call 999 immediately – adrenaline is a first response, not a replacement for emergency care.

• Report any side effects through the MHRA Yellow Card scheme (online or via the app).

Why This Matters

For some, using an auto-injector can feel daunting. Needle anxiety, worries about storage, or confusion about how to use the device can all delay life-saving treatment. A nasal spray option may give more people the confidence to act quickly – which can make all the difference in an emergency.

When Will It Be Available?

EURneffy® was officially approved on 18 July 2025. It is expected to be launched in the UK later this year, once final access arrangements are confirmed.

Final Thoughts

Anaphylaxis is frightening, but with the right awareness and access to treatment, lives can be saved. Whether it’s an auto-injector or the new nasal spray, the most important thing is being prepared and acting fast.

If you or someone you care for is at risk of anaphylaxis, speak to your GP, allergy specialist, or pharmacist about the best treatment options available.

Inquire about our First Aid Training Courses to learn more about Anaphylaxis.